Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 12738S

12738S 1 Kit (6 x 40 µl) $429.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Product Includes Quantity Applications Reactivity MW(kDa) Isotype
Phospho-CENP-A (Ser7) Antibody 2187 40 µl
H 17 Rabbit 
Phospho-Histone H3 (Ser10) (D2C8) XP® Rabbit mAb 3377 40 µl
H M R Mk Z 17 Rabbit IgG
Phospho-Histone H3 (Ser28) Antibody 9713 40 µl
H M Hm Dm 17 Rabbit 
Phospho-p53 (Ser315) Antibody 2528 40 µl
H 53 Rabbit 
Phospho-PLK1 (Thr210) (D5H7) Rabbit mAb 9062 40 µl
H 62 Rabbit IgG
Phospho-TACC3 (Ser558) (D8H10) XP® Rabbit mAb 8842 40 µl
H 140 Rabbit IgG
Anti-rabbit IgG, HRP-linked Antibody 7074 100 µl
All Goat 

Product Description

The Aurora A/B Substrate Antibody Sampler Kit provides an economical means to investigate the G2/M phase of the cell cycle. The kit contains enough primary antibody to perform four western blots per primary antibody.


Specificity / Sensitivity

Each antibody in the Aurora Antibody Sampler Kit detects endogenous levels of its respective modification-specific target protein and does not cross-react with other family members.


Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide and are purified by protein A and peptide affinity chromatography. Monoclonal antibodies are produced by immunizing animals with recombinant human proteins or synthetic peptides.

Aurora kinases belong to a highly conserved family of mitotic serine/threonine kinases with three members identified among mammals: Aurora A, B, and C (1,2). Studies on the temporal expression pattern and subcellular localization of Aurora kinases in mitotic cells suggest an association with mitotic structure. Aurora kinase functional influences span from G2 phase to cytokinesis and may be involved in key cell cycle events such as centrosome duplication, chromosome bi-orientation and segregation, cleavage furrow positioning, and ingression (3). Aurora A is detected at the centrosomes, along mitotic spindle microtubules, and in the cytoplasm of mitotically proliferating cells. Aurora A protein levels are low during G1 and S phases and peak during the G2/M phase of the cell cycle. Phosphorylation of Aurora A at Thr288 in its catalytic domain increases kinase activity. Aurora A is involved in centrosome separation, maturation, and spindle assembly and stability. Expression of Aurora B protein also peaks during the G2/M phase of the cell cycle; Aurora B kinase activity peaks at the transition from metaphase to the end of mitosis. Aurora B associates with chromosomes during prophase prior to relocalizing to the spindle at anaphase. Aurora B regulates chromosome segregation through the control of microtubule-kinetochore attachment and cytokinesis. Expression of both Aurora A and Aurora B during the G2/M phase transition is tightly coordinated with histone H3 phosphorylation (4,5); research investigators have observed overexpression of these kinases in a variety of human cancers (2,4). Aurora C localizes to the centrosome from anaphase to cytokinesis and both mRNA and protein levels peak during G2/M phase. Although typical Aurora C expression is limited to the testis, research studies report overexpression of Aurora C is detected in various cancer cell lines (6).


Transforming acid coiled-coil (TACC) proteins are a family of proteins characterized by a common coiled-coil motif of approximately 200 amino acids at the carboxy-terminal end (7). When phosphorylated at Ser558 by Aurora A, mammalian TACC3 is localized to mitotic spindles and increases microtubule stability (8,9).

Aurora A-dependent phosphorylation of CENP-A on Ser7 during prophase is required for proper targeting of Aurora B to the inner centromere in prometaphase, proper kinetochore/microtubule attachment and proper alignment of chromosomes during mitosis (10). Aurora B also targets Ser7 on CENP-A, which in turn regulates Aurora B activity during cytokinesis (11). Aurora B phosphorylates both Ser10 and Ser28 on histone H3 in concordance with mitotic chromosome condensation (12).

Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (13). Aurora A phosphorylates p53 at Ser315 in a cell cycle-dependent manner leading to MDM2-mediated ubiquitination/degradation of p53 (14). Aurora A phosphorylation of Thr210 on PLK promotes mitotic entry following checkpoint-dependent cell cycle arrest (15).


1.  Warner, S.L. et al. (2003) Mol Cancer Ther 2, 589-95.

2.  Katayama, H. et al. (2003) Cancer Metastasis Rev 22, 451-64.

3.  Andrews, P.D. et al. (2003) Curr Opin Cell Biol 15, 672-83.

4.  Pascreau, G. et al. (2003) Prog Cell Cycle Res 5, 369-74.

5.  Crosio, C. et al. (2002) Mol Cell Biol 22, 874-85.

6.  Kimura, M. et al. (1999) J Biol Chem 274, 7334-40.

7.  Levine, A.J. (1997) Cell 88, 323-31.

8.  Gergely, F. et al. (2000) Proc Natl Acad Sci U S A 97, 14352-7.

9.  Kinoshita, K. et al. (2005) J Cell Biol 170, 1047-55.

10.  Schneider, L. et al. (2007) J Biol Chem 282, 29273-83.

11.  Kunitoku, N. et al. (2003) Dev Cell 5, 853-64.

12.  Zeitlin, S.G. et al. (2001) J Cell Biol 155, 1147-57.

13.  Goto, H. et al. (2002) Genes Cells 7, 11-7.

14.  Sakaguchi, K. et al. (1998) Genes Dev 12, 2831-41.

15.  Macůrek, L. et al. (2008) Nature 455, 119-23.


Entrez-Gene Id 1058, 8350, 5347, 7157, 10460
Swiss-Prot Acc. P49450, P68431, P53350, P04637, Q9Y6A5

Protein Specific References

Zhong S et al. (2001) J Biol Chem 276, 33213–9

Li F et al. (2002) EMBO Rep 3, 767–73

Li J et al. (2002) J Biol Chem 277, 49504–10

Sugiyama K et al. (2002) Oncogene 21, 3103–11

Martens JH et al. (2003) Mol Cell Biol 23, 1808–16

Espino PS et al. (2006) Cancer Res 66, 4610–6

Park JH et al. (2006) Cancer Res 66, 9186–95

Soncini C et al. (2006) Clin Cancer Res 12, 4080–9

Idikio HA and (2006) Anticancer Res 26, 4687–94

Wang GG et al. (2007) Nat Cell Biol 9, 804–12

Duan Q et al. (2008) J Biol Chem 283, 33585–90

Dawson MA et al. (2009) Nature 461, 819–22

Cheng MF et al. (2009) Histol Histopathol 24, 1105–11

Hurd PJ et al. (2009) J Biol Chem 284, 16575–83

McGinty RK et al. (2009) ACS Chem Biol 4, 958–68

Banck MS et al. (2009) Epigenetics 4, 100–6

Wu Y et al. (2010) BMC Cancer 10, 32

Pasini D et al. (2010) Nucleic Acids Res 38, 4958–69

Sakabe K and Hart GW (2010) J Biol Chem 285, 34460–8

Gehani SS et al. (2010) Mol Cell 39, 886–900

Jung HR et al. (2010) Mol Cell Proteomics 9, 838–50

Davies GF et al. (2010) Cancer Lett 288, 236–50

Aguilera C et al. (2011) Nature 469, 231–5

Huertas D et al. (2012) Oncogene 31, 1408–18

Joosten M et al. (2013) Haematologica 98, 247–54

Sayegh J et al. (2013) J Biol Chem 288, 9408–17

Dai, J. et al. (2005) Genes Dev 19, 472-88.

Zhong S et al. (2001) J Biol Chem 276, 33213–9

Li F et al. (2002) EMBO Rep 3, 767–73

Li J et al. (2002) J Biol Chem 277, 49504–10

Sugiyama K et al. (2002) Oncogene 21, 3103–11

Martens JH et al. (2003) Mol Cell Biol 23, 1808–16

Espino PS et al. (2006) Cancer Res 66, 4610–6

Park JH et al. (2006) Cancer Res 66, 9186–95

Soncini C et al. (2006) Clin Cancer Res 12, 4080–9

Idikio HA and (2006) Anticancer Res 26, 4687–94

Wang GG et al. (2007) Nat Cell Biol 9, 804–12

Duan Q et al. (2008) J Biol Chem 283, 33585–90

Dawson MA et al. (2009) Nature 461, 819–22

Cheng MF et al. (2009) Histol Histopathol 24, 1105–11

Hurd PJ et al. (2009) J Biol Chem 284, 16575–83

McGinty RK et al. (2009) ACS Chem Biol 4, 958–68

Banck MS et al. (2009) Epigenetics 4, 100–6

Wu Y et al. (2010) BMC Cancer 10, 32

Pasini D et al. (2010) Nucleic Acids Res 38, 4958–69

Sakabe K and Hart GW (2010) J Biol Chem 285, 34460–8

Gehani SS et al. (2010) Mol Cell 39, 886–900

Jung HR et al. (2010) Mol Cell Proteomics 9, 838–50

Davies GF et al. (2010) Cancer Lett 288, 236–50

Aguilera C et al. (2011) Nature 469, 231–5

Huertas D et al. (2012) Oncogene 31, 1408–18

Joosten M et al. (2013) Haematologica 98, 247–54

Sayegh J et al. (2013) J Biol Chem 288, 9408–17

Dai, J. et al. (2005) Genes Dev 19, 472-88.

van de Weerdt BC et al. (2005) Mol Cell Biol 25, 2031–44

Tang J et al. (2008) Oncogene 27, 6635–45

Chehab NH et al. (1999) Proc Natl Acad Sci U S A 96, 13777–82

Buschmann T et al. (2000) Cancer Res 60, 896–900

Chehab NH et al. (2000) Genes Dev 14, 278–88

Persons DL et al. (2000) J Biol Chem 275, 35778–85

Vaziri H et al. (2001) Cell 107, 149–59

Minamoto T et al. (2001) Oncogene 20, 3341–7

Stewart ZA et al. (2001) Oncogene 20, 113–24

Bean LJ and Stark GR (2001) Oncogene 20, 1076–84

Xie S et al. (2001) J Biol Chem 276, 43305–12

Xie S et al. (2001) J Biol Chem 276, 36194–9

Kim SJ et al. (2002) J Biol Chem 277, 33501–8

Bulavin DV et al. (2002) Nat Genet 31, 210–5

Shono T et al. (2002) Cancer Res 62, 1069–76

Adamson AW et al. (2002) J Biol Chem 277, 38222–9

Hase H et al. (2002) J Biol Chem 277, 46950–8

Bischof O et al. (2002) EMBO J 21, 3358–69

Qin JZ et al. (2002) Oncogene 21, 2991–3002

Hofmann TG et al. (2002) Nat Cell Biol 4, 1–10

Chouinard N et al. (2002) Biochem J 365, 133–45

Shiseki M et al. (2003) Cancer Res 63, 2373–8

Chen K et al. (2003) J Biol Chem 278, 39527–33

Sengupta S et al. (2003) EMBO J 22, 1210–22

Urban G et al. (2003) J Biol Chem 278, 9747–53

Oguchi K et al. (2003) Blood 101, 3622–7

Hideshima T et al. (2003) Blood 101, 1530–4

Lindström MS and Wiman KG (2003) Oncogene 22, 4993–5005

Hofseth LJ et al. (2003) Proc Natl Acad Sci U S A 100, 143–8

Wang C and Chen J (2003) J Biol Chem 278, 2066–71

Matsuoka M et al. (2003) Environ Health Perspect 111, 509–12

Yanamadala S and Ljungman M (2003) Mol Cancer Res 1, 747–54

Möller A et al. (2003) Cancer Res 63, 4310–4

Goudelock DM et al. (2003) J Biol Chem 278, 29940–7

Louria-Hayon I et al. (2003) J Biol Chem 278, 33134–41

Tritarelli A et al. (2004) Mol Biol Cell 15, 3751–7

Mroz RM et al. (2004) Am J Respir Cell Mol Biol 30, 564–8

Rui Y et al. (2004) EMBO J 23, 4583–94

Li Y et al. (2004) Oncogene 23, 7355–65

Vaghefi H and Neet KE (2004) Oncogene 23, 8078–87

Nair VD et al. (2004) J Biol Chem 279, 27494–501

Takagi M et al. (2004) Blood 103, 283–90

Ito K et al. (2004) Cancer Res 64, 1071–8

Koutsodontis G and Kardassis D (2004) Oncogene 23, 9190–200

Jackson MW et al. (2004) Oncogene 23, 4477–87

Dohoney KM et al. (2004) Oncogene 23, 49–57

Thompson T et al. (2004) J Biol Chem 279, 53015–22

Yeh PY et al. (2004) Oncogene 23, 3580–8

Komiyama S et al. (2004) Biochem Biophys Res Commun 323, 816–22

Soubeyrand S et al. (2004) Eur J Biochem 271, 3776–84

Ou YH et al. (2005) Mol Biol Cell 16, 1684–95

Feki A et al. (2005) Oncogene 24, 3726–36

Li Z et al. (2005) J Biol Chem 280, 16843–50

Di Stefano V et al. (2005) Oncogene 24, 5431–42

Hershko T et al. (2005) Cell Death Differ 12, 377–83

Mayo LD et al. (2005) J Biol Chem 280, 25953–9

Wesierska-Gadek J et al. (2005) Mol Cancer Ther 4, 113–24

Wang L et al. (2005) Oncogene 24, 3020–7

Zhao Y et al. (2006) Mol Cell Biol 26, 2782–90

Gresko E et al. (2006) EMBO J 25, 1883–94

Ichwan SJ et al. (2006) Oncogene 25, 1216–24

Knights CD et al. (2006) J Cell Biol 173, 533–44

Moiseeva O et al. (2006) Mol Biol Cell 17, 1583–92

Zeng PY and Berger SL (2006) Cancer Res 66, 10701–8

Li AG et al. (2006) Mol Cell 23, 575–87

Yoshida K et al. (2006) J Biol Chem 281, 5734–40

Li DW et al. (2006) Oncogene 25, 3006–22

Fraser M et al. (2006) Oncogene 25, 2203–12

Paulsen MT et al. (2006) Mol Cancer 5, 25

Singh K et al. (2007) PLoS One 2, e660

Nag A et al. (2007) J Biol Chem 282, 8812–20

Li HH et al. (2007) EMBO J 26, 402–11

Li Q et al. (2007) Cancer Res 67, 66–74

Taira N et al. (2007) Mol Cell 25, 725–38

Lambrot R et al. (2007) J Clin Endocrinol Metab 92, 2632–9

Ivanov GS et al. (2007) Mol Cell Biol 27, 6756–69

Nakanishi M et al. (2007) J Biol Chem 282, 22993–3004

Liu Y et al. (2007) J Biol Chem 282, 2505–11

Derheimer FA et al. (2007) Proc Natl Acad Sci U S A 104, 12778–83

Lee JH et al. (2007) J Cell Sci 120, 2259–71

Mantovani F et al. (2007) Nat Struct Mol Biol 14, 912–20

Wang H et al. (2008) J Biol Chem 283, 2564–74

Sun L et al. (2008) J Exp Clin Cancer Res 27, 35

Chang PC and Li M (2008) J Virol 82, 278–90

Lin T et al. (2008) Toxicology 247, 145–53

Chen JJ et al. (2008) J Immunol 180, 8030–9

Shouse GP et al. (2008) Mol Cell Biol 28, 448–56

Kitagawa M et al. (2008) Mol Cell 29, 217–31

Habold C et al. (2008) J Cell Mol Med 12, 607–21

Zhu H et al. (2008) Int J Cancer 123, 2741–9

Yamaguchi H et al. (2009) J Biol Chem 284, 11171–83

Wang Z et al. (2009) Pharm Res 26, 1140–8

Bar JK et al. (2009) Int J Gynecol Cancer 19, 1322–8

Nishimura T et al. (2009) J Biol Chem 284, 36442–52

Puca R et al. (2009) Mol Cancer 8, 85

Yadavilli S et al. (2009) J Biochem Mol Toxicol 23, 373–86

Baxter EW and Milner J (2010) J Neurooncol 97, 373–82

Fraser JA et al. (2010) J Biol Chem 285, 37773–86

Fraser JA et al. (2010) J Biol Chem 285, 37762–72

Shang X et al. (2010) Oncogene 29, 4938–46

Chen X et al. (2010) J Biol Chem 285, 12823–30

Kawano T et al. (2010) Int J Oncol 37, 787–95

Moehlenbrink J et al. (2010) Cancer Lett 292, 119–24

Venerando A et al. (2010) Cell Mol Life Sci 67, 1105–18

Puca R et al. (2010) Free Radic Biol Med 48, 1338–46

Marchenko ND et al. (2010) Cell Death Differ 17, 255–67

Aranha MM et al. (2011) PLoS One 6, e21396

Muñoz-Fontela C et al. (2011) Cell Cycle 10, 3701–5

Wu L et al. (2011) J Biol Chem 286, 2236–44

Ozeki C et al. (2011) J Biol Chem 286, 18251–60

Mellert HS et al. (2011) J Biol Chem 286, 4264–70

Valbuena A et al. (2011) PLoS One 6, e17320

Xu S et al. (2011) J Cardiovasc Pharmacol 58, 263–71

Seo SK et al. (2011) J Thorac Oncol 6, 1313–9

Savelyeva I and Dobbelstein M (2011) Oncogene 30, 865–75

Wu ZZ et al. (2011) J Cell Physiol 226, 2415–28

Smeenk L et al. (2011) PLoS One 6, e17574

Grison A et al. (2011) Proc Natl Acad Sci U S A 108, 17979–84

Gully CP et al. (2012) Proc Natl Acad Sci U S A 109, E1513–22

Wang H et al. (2012) DNA Repair (Amst) 11, 146–56

Xu S et al. (2013) Cell Res 23, 423–35

Chan C et al. (2013) Mol Cell Biol 33, 485–97

Thakur BK et al. (2013) Int J Cancer 132, 766–74

Yang Y et al. (2013) J Biol Chem 288, 529–39


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
XP® is a trademark of Cell Signaling Technology, Inc.